# US 7,744,929 B2 · Botanical drug compositions for treatments of liver and immunological disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,744,929 B2
- Document ID: US7744929B2
- Status: Granted
- Kind: B2
- Application number: 10/662,777
- Filed: 2003-09-15
- Published: 2005-03-17
- Granted: 2010-06-29
- Earliest claimed: 2003-09-15
- Assignees: Ambotan Pharma, LLC
- Inventors: Hassan Ahmad; Ismail Elchagea; Ezz Hamza
- Web page: https://patentgrep.com/patent/US7744929B2

## CPC

- A61K 36/71: Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to compositions comprising the botanicals from the Family Ranunculaceae, Subclass: Dicotyledonae; Crassinucelli, Superorder: Ranunculales. Examples of these botanicals include but are not limited to; Actaea, Anemone, Ranunculus, and Nigella, or extracts thereof, which are useful in treating liver diseases, particularly those with viral etiology. More specifically, the compositions of the present invention are derived from various botanicals or medicinal plants. The compositions of the invention have demonstrated outstanding efficacy for treatment of patients with hepatic disorders. Compositions of the present invention have also exhibited immunomodulatory activities. The preferred compositions contain the botanical ingredients in concentrations of not less than 20% w/v. The treatment can be therapeutic or prophylactic and may be administered orally, parenterally, as suppository or via nasal mucosa. The treatment may be delivered in a single dose, multi-doses or via a slow release mechanism.

## Claims

### Claim 1

A pharmaceutical composition for treating a hepatic disorder and/or for increasing the number of immune cells and platelets in a patient consisting essentially of a therapeutically effective amount of a buffered aqueous extract of Actaea rubra, Anemone hepatica, Anemone nemorosa, Nigella sativa, and Ranunculus arvensis, and a pharmaceutically acceptable carrier, wherein the extract is present in a concentration of not less than 20% weight per volume.

### Claim 2 (depends on 1)

A composition according to claim 1, wherein the composition is in a form of a tablet or capsule.

### Claim 3 (depends on 1)

A composition according to claim 1, wherein the composition is in a form of a liquid or suspension.

### Claim 4 (depends on 1)

A composition according to claim 1, wherein the composition is in a form of a sterile preparation for intra-muscular, subcutaneous, or intra-venous injection.

### Claim 5 (depends on 1)

A composition according to claim 1, wherein the composition is in a form of nasal spray.

### Claim 6 (depends on 1)

A composition according to claim 1, wherein the composition is in a form of a topical application.

### Claim 7 (depends on 1)

A composition according to claim 1, wherein the composition is in a form of a transdermal system.

### Claim 8 (depends on 1)

A composition according to claim 1, wherein the composition is in a form of suppository.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is effective for treating patients suffering from a hepatic disorder selected from the group consisting of chronic hepatitis, advanced/late stage hepatitis, hepatitis caused by hepatitis virus genotypes I, II, III or IV, a hepatic disorder characterized by fibrosis and/or cirrhosis, a hepatic disorder resulting from an autoimmune disease and a hepatic disorder resulting from a drug treatment.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the patients suffering from said hepatic disorder exhibit advanced stage liver disease characterized by fibrosis and cirrhosis, and wherein treating with said composition results in modifying disease activity, including but not limited to, a decrease in hepatitis viral load, and a decrease in liver enzymes alanine aminotransferase (ALT) levels and aspartate aminotransferase (AST) levels.

### Claim 11 (depends on 1)

The composition of claim 1, wherein said composition is effective in treating the cirrhosis and fibrosis associated with an advanced/late stage hepatic disorder.